Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KESTREL: Brolucizumab vs Aflibercept in Diabetic Macular Edema
NCT03481634Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2018
- Primary completion
- Nov 2020
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of brolucizumab in diabetic macular edema (DME), sponsored by Novartis. Started Jul 2018; status: completed.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03481634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03481634.